menu
    • menu
    [{"orgOrder":0,"company":"Arthrosi Therapeutics","sponsor":"Prime Eight Capital Limited","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Series E Financing","leadProduct":"Pozdeutinurad","moa":"SLC22A12","graph1":"Rheumatology","graph2":"Phase III","graph3":"Arthrosi Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0.14999999999999999,"dosageForm":"Capsule","sponsorNew":"Arthrosi Therapeutics \/ Prime Eight Capital Limited","highestDevelopmentStatusID":"10","companyTruncated":"Arthrosi Therapeutics \/ Prime Eight Capital Limited"},{"orgOrder":0,"company":"Arthrosi Therapeutics","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Pozdeutinurad","moa":"URAT1","graph1":"Rheumatology","graph2":"Phase III","graph3":"Arthrosi Therapeutics","amount2":1.5,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":1.5,"dosageForm":"Capsule","sponsorNew":"Arthrosi Therapeutics \/ Sobi","highestDevelopmentStatusID":"10","companyTruncated":"Arthrosi Therapeutics \/ Sobi"}]

    Find Clinical Drug Pipeline Developments & Deals for Pozdeutinurad

    Menu

    Pozdeutinurad

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Arthrosi Therapeutics

                            U.S.A arrow
                            Pharmapack
                            Not Confirmed

                            Arthrosi Therapeutics

                            U.S.A arrow
                            Pharmapack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pozdeutinurad

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase III

                            Sponsor : Swedish Orphan Biovitrum AB

                            Deal Size : $1,500.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Sobi Acquires Arthrosi Therapeutics to Enhance Gout Pipeline

                            Details : Through the acquisition of Pozdeutinurad, a miscellaneous product targeting URAT1, the deal aims to advance the treatment of gout.

                            Product Name : AR882

                            Product Type : Miscellaneous

                            Upfront Cash : $1,500.0 million

                            December 14, 2025

                            Lead Product(s) : Pozdeutinurad

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase III

                            Sponsor : Swedish Orphan Biovitrum AB

                            Deal Size : $1,500.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Arthrosi Therapeutics

                            U.S.A arrow
                            Pharmapack
                            Not Confirmed

                            Arthrosi Therapeutics

                            U.S.A arrow
                            Pharmapack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pozdeutinurad

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase III

                            Sponsor : Prime Eight Capital Limited

                            Deal Size : $153.0 million

                            Deal Type : Series E Financing

                            DEALS_DEV arrow-down

                            Arthrosi Raises $153M, Fueling Dash Toward Phase 3 Gout Data

                            Details : Arthrosi plans to use the proceeds from this financing to complete the clinical development of its lead program, AR882 (pozdeutinurad) for the treatment of gout and tophaceous gout.

                            Product Name : AR882

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 08, 2025

                            Lead Product(s) : Pozdeutinurad

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase III

                            Sponsor : Prime Eight Capital Limited

                            Deal Size : $153.0 million

                            Deal Type : Series E Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.